2Zhang W,Doherty M,Bardin T,et al.EULAR evidence based recommendations for gout.Part Ⅱ:management.Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)[J].Ann Rheum Dis,2006,65(10):1312-1324.
6[2]Mikuls TR,Farrar JT,Bilker WB,et al.Gout epidemiology:results from the UK General Practice Research Database,1990-1999.Ann Rheum Dis,2005,64:267-272
7[5]Shaun Ruddy,Edward D Harrins,Clement B Sledge.Kelley's Textbook of Rheumatology.Saunders Company,2001.1339-1376
8[6]Becher MA,Schumacher HR,Wortamann RL,et al.Febuxostat compared with allopurinol in patients with hyperuricemia and gout.N Engl J Med,2005,353:2450-2461
9[7]Mayer MD,Khoaravan R,et al.Pharmacokinetics and pharmacodynamics of febuxostat,a new non-purine selective inhibitor of xanthine oxidase,in subjects with renal impairment.Am J Ther,2005,12:22-34
10[8]Takano Y,Hase-Aoki K,et al.Selectivity of febuxostat,a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase.Life Sci,2005,76:1835-1847
4Vera J, Curto R, Tortes NV. Detection of potential enzyme targets by metabolic modelling and optimization:Application to a simple enzy- mopathy [ J ]. Bioinformatics ,2007,23 ( 17 ) : 2281-2289.
5Choi HK. A prescription for lifestyle change in patients with hyperuri- cemia and gout [ J ]. Current opinion in rheumatology, 2010,22 ( 2 ) : 165-172.
6Lehto S, Niskanen L, R6nnemaa T, et al. Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus[J]. Stroke, 1998,29(3) : 635-639.
8Tsai EC, Boyko EJ, Leonetti DL, et al. Low serum testosterone level as a predictor of increased visceral fat in Japanese-American memEJ. Int J Obes Relat Metab Disord,2000,24(4):485-491.
